OLO (NYSE:OLO – Get Rating) and Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Analyst Recommendations
This is a breakdown of current ratings and price targets for OLO and Protagenic Therapeutics, as reported by MarketBeat.com.
Get
OLO alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| OLO | 0 | 0 | 4 | 0 | 3.00 |
| Protagenic Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
OLO currently has a consensus price target of $27.60, suggesting a potential upside of 150.91%. Protagenic Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 566.67%. Given Protagenic Therapeutics' higher probable upside, analysts clearly believe Protagenic Therapeutics is more favorable than OLO.
Profitability
This table compares OLO and Protagenic Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| OLO | -17.52% | -3.09% | -2.81% |
| Protagenic Therapeutics | N/A | -46.99% | -41.99% |
Institutional & Insider Ownership
75.3% of OLO shares are held by institutional investors. Comparatively, 11.1% of Protagenic Therapeutics shares are held by institutional investors. 45.0% of Protagenic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
OLO has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
Valuation & Earnings
This table compares OLO and Protagenic Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| OLO | $149.37 million | 11.71 | -$42.27 million | ($0.18) | -61.11 |
| Protagenic Therapeutics | N/A | N/A | -$4.52 million | N/A | N/A |
Protagenic Therapeutics has lower revenue, but higher earnings than OLO.
Summary
OLO beats Protagenic Therapeutics on 6 of the 10 factors compared between the two stocks.
About OLO
(Get Rating)
Olo Inc. provides software-as-a-service platform for multi-location restaurants in the United States. The company's platform enables on-demand commerce operations, which cover digital ordering and delivery through online and mobile ordering modules. Its modules include Order Management, an on-demand digital commerce and channel management solutions that enables consumers to order directly from and pay restaurants via mobile, web, kiosk, voice, and other digital channels; and Delivery Enablement, a fulfillment network, as well as a network aggregator and channel management solution, which enables restaurants to offer, manage, and expand direct delivery, as well as allows restaurants to control and syndicate menu, pricing, location data, and availability, while directly integrating and optimizing orders from third-parties into the restaurants' point-of-sale and systems. The company also provides Customer Engagement solution, a suite of restaurant-centric marketing and sentiment solutions that enables restaurants to collect, analyze, and act on guest data; Front-of-House solution, which enables restaurants to streamline the queue orders from multiple sales channels; and Payment solution, a payment platform that offers fraud prevention that results in enhanced authorization rates for valid transactions. The company was formerly known as Mobo Systems, Inc. and changed its name to Olo Inc. in January 2020. Olo Inc. was incorporated in 2005 and is headquartered in New York, New York.
About Protagenic Therapeutics
(Get Rating)
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Receive News & Ratings for OLO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLO and related companies with MarketBeat.com's FREE daily email newsletter.
